All this translates into an improvement in glycemic control and dyslipidemia, a reduction in blood pressure, weight, and ectopic visceral fat deposits, as well as inflammation and coagulation, which could translate into greater cardiovasculorenal protection with the use of these drugs
Major trials conducted in patients with MASLD have reported prevalence rates of 4246%, 1938%, and 1519% for these symptoms, respectively
multivariable analysis of the significance of GLP-1R expression was conducted by logistic regression
One potential cost advantage: oral medications eliminate the expenses associated with injection supplies (needles, syringes, sharps containers, alcohol swabs) that add up over months and years of treatment
As mentioned above, there is no formal GLP-1 diet plan